Vascepa (icosapent ethyl) is a prescription medication used to lower triglyceride levels in adults with severe hypertriglyceridemia [1]. According to a study published in the Journal of Clinical Lipidology, Vascepa can improve lipid profiles in patients taking statins [3].

Hypertriglyceridemia is a condition where there are high levels of triglycerides in the blood, which can lead to an increased risk of cardiovascular disease [2]. According to UpToDate, treatment for hypertriglyceridemia includes lifestyle modifications such as diet and exercise, as well as medication such as statins and fibrates [2].

A study published in the Journal of Clinical Lipidology found that Vascepa, when used in combination with statins, can significantly reduce triglyceride levels and improve other lipid profiles such as LDL cholesterol and non-HDL cholesterol [3]. The study also found that Vascepa was well-tolerated and did not cause any significant adverse effects [3].

In conclusion, Vascepa can improve lipid profiles in patients taking statins. It is important to note that Vascepa is specifically indicated for the treatment of severe hypertriglyceridemia and should only be used under the guidance of a healthcare professional [1]. Additionally, lifestyle modifications such as diet and exercise should also be incorporated into the treatment plan for hypertriglyceridemia [2].

Sources:
[1] DrugPatentWatch. (2021). Vascepa. Retrieved from https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] UpToDate. (2021). Hypertriglyceridemia in adults: Management. Retrieved from https://www.uptodate.com/contents/hypertriglyceridemia-in-adults-management
[3] Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2016). Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). Journal of Clinical Lipidology, 10(2), 256-265. doi: 10.1016/j.jacl.2015.12.010